South Korea Puts $21 Million Behind Minor Cannabinoids for Medical Hemp Products

South Korea is investing 29.6 billion won (about $21 million) to move its pioneering industrial hemp program into a new commercialization phase, signaling that medical applications remain the government's top priority for the crop. The four-year project will expand the Andong Industrial Hemp Special Zone in North Gyeongsang Province, aiming to commercialize minor cannabinoids such as CBG, CBC and CBN. Participating companies include Neoken Bio and HLB Life Science R&D, working alongside KIST to build a full pharmaceutical value chain from cultivation to finished medicines.

For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.